兰地洛尔治疗脓毒症相关快速性心律失常的疗效与安全性(J-Land 3S):多中心开放标签随机对照试验
J-Land 3S 是一项在日本54家医院开展的多中心开放标签随机对照试验,纳入151例ICU内脓毒症或脓毒性休克合并快速性心律失常患者。兰地洛尔组在常规治疗基础上以1 μg/kg/min起始静脉泵入,最大20 μg/kg/min,主要终点为随机后24小时心率60-94 bpm的比例。结果显示兰地洛尔组55%达标 vs 对照组33%,组间差异23.1%(95%CI 7.1-37.5;p=0.0031),严重不良事件发生率两组相近,但兰地洛尔组有5例(6%)发生药物相关严重不良事件,包括血压下降3例(4%)以及心脏骤停、心率下降、射血分数下降各1例(1%)。作者认为兰地洛尔可显著提高心率达标率并减少新发心律失常,但需在适当监测血压和心率下使用。
要点
- 脓毒症相关快速性心律失常患者,常规治疗加兰地洛尔组24小时心率60-94 bpm达标率55%(41/75)vs 对照组33%(25/75),差异23.1%(95%CI 7.1-37.5;p=0.0031)。
- 兰地洛尔组药物相关严重不良事件5/77(6%),包括血压下降3例(4%)、心脏骤停、心率下降、射血分数下降各1例(1%)。
- 总体不良事件兰地洛尔组49/77(64%)vs 对照组44/74(59%),严重不良事件(含导致死亡的不良事件)9/77(12%)vs 8/74(11%)。
- 作者认为兰地洛尔需在适当监测血压和心率下使用,因脓毒症和脓毒性休克患者存在低血压风险。
适用人群与场景
- ICU内接受常规脓毒症治疗(依据脓毒症管理临床指南,包括呼吸与液体复苏、抗菌药物、儿茶酚胺)后出现快速性心律失常的成人患者(≥20岁)。
- 纳入标准:符合第三次国际脓毒症与脓毒性休克共识定义的脓毒症诊断;使用儿茶酚胺维持平均动脉压≥65 mmHg至少1小时;心率≥100 bpm持续至少10分钟且儿茶酚胺剂量不变,诊断为心房颤动、心房扑动或窦性心动过速。
- 仅纳入随机前24小时内出现上述症状和体征、且进入ICU后72小时内出现者。
诊断标准与关键阈值
- 脓毒症诊断依据第三次国际脓毒症与脓毒性休克共识定义。
- 快速性心律失常:心率≥100 bpm持续至少10分钟且儿茶酚胺剂量不变,诊断为心房颤动、心房扑动或窦性心动过速。
- 主要终点达标:随机后24小时心率60-94 bpm;24小时无心率数据者按无应答处理。
处置流程与药物剂量
- 两组均接受常规治疗(依据2016年日本脓毒症与脓毒性休克管理临床实践指南),包括呼吸与液体复苏、抗菌药物、儿茶酚胺。
- 兰地洛尔组:随机后2小时内开始盐酸兰地洛尔静脉泵入,起始剂量1 μg/kg/min,按研究方案可增至最大20 μg/kg/min。
- 随机前治疗医师需先稳定患者血流动力学状态。
- 作者认为兰地洛尔应在适当监测血压和心率下使用,因脓毒症和脓毒性休克患者存在低血压风险。
红旗征与不能漏的情况
- 药物相关严重不良事件包括血压下降3例(4%)、心脏骤停1例(1%)、心率下降1例(1%)、射血分数下降1例(1%)。
研究设计与关键结果
- 多中心、开放标签、随机对照试验,在日本54家医院开展,2018年1月16日至2019年4月22日随机151例,兰地洛尔组76例、对照组75例。
- 主要终点:兰地洛尔组24小时心率60-94 bpm达标率55%(41/75)vs 对照组33%(25/75),组间差异23.1%(95%CI 7.1-37.5;p=0.0031)。
- 不良事件:兰地洛尔组49/77(64%)vs 对照组44/74(59%);严重不良事件(包括导致死亡的不良事件)兰地洛尔组9/77(12%)vs 对照组8/74(11%)。
- 兰地洛尔相关严重不良事件5/77(6%),包括血压下降3例(4%)、心脏骤停、心率下降、射血分数下降各1例(1%)。
- 作者报告兰地洛尔显著减少新发心律失常发生率。
证据类型、等级与局限
- 证据类型:多中心、开放标签、随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对ICU内脓毒症相关快速性心律失常(心房颤动、心房扑动或窦性心动过速)患者,在常规脓毒症治疗和血流动力学稳定基础上,加用兰地洛尔静脉泵入(起始1 μg/kg/min,最大20 μg/kg/min)可提高24小时心率(60-94 bpm)达标率。
- 作者认为兰地洛尔耐受性良好,但需在适当监测血压和心率下使用,因脓毒症和脓毒性休克患者存在低血压风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Tachycardia and atrial fibrillation frequently occur in patients being treated for sepsis or septic shock and have a poor prognosis. Treatments for tachyarrhythmias are often ineffective or contraindicated in this setting. We aimed to investigate the efficacy and safety of landiolol, an ultra-short-acting β-blocker, for treating sepsis-related tachyarrhythmias.
METHODS: We did a multicentre, open-label, randomised controlled trial at 54 hospitals in Japan. Patients admitted to the intensive care units who received conventional treatment for sepsis, according to clinical guidelines for the management of sepsis, and who subsequently developed a tachyarrhythmia, were enrolled. The main inclusion criteria were 20 years of age or older, diagnosis of sepsis according to Third International Consensus Definitions for Sepsis and Septic Shock criteria, administration of catecholamine necessary to maintain mean arterial pressure at 65 mm Hg or more for at least 1 h, and heart rate of 100 beats per min (bpm) or more maintained for at least 10 min without a change in catecholamine dose with diagnosis of atrial fibrillation, atrial flutter, or sinus tachycardia. Only patients who developed these symptoms and signs within 24 h before randomisation, and within 72 h after entering an intensive care unit, were prospectively assigned to receive conventional sepsis therapy alone (control group) or conventional sepsis therapy plus landiolol (landiolol group) in an open-label manner. Landiolol hydrochloride was intravenously infused at an initial dose of 1 μg/kg per min within 2 h after randomisation and the dose could be increased per study protocol to a maximum of 20 μg/kg per min. Patients in both groups received conventional therapy (Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock 2016), including respiratory and fluid resuscitation, antimicrobials, and catecholamines. The treating physicians were required to stabilise the patient's haemodynamic status before randomisation. Randomisation was done using a central randomisation system and dynamic allocation with the minimisation method by institution, heart rate at randomisation (≥100 to <120 bpm or ≥120 bpm), and age (<70 years or ≥70 years). The primary outcome was the proportion of patients with heart rate of 60-94 bpm at 24 h after randomisation. Patients without heart rate data at 24 h after randomisation were handled as non-responders. The primary outcome was analysed using the full analysis set on an as-assigned basis, while safety was analysed using the safety analysis set according to the treatment received. This study was registered with the Japan Pharmaceutical Information Center Clinical Trials Information database, number JapicCTI-173767.
FINDINGS: Between Jan 16, 2018 and Apr 22, 2019, 151 patients were randomly assigned, 76 to the landiolol group and 75 to the control group. A significantly larger proportion of patients in the landiolol group had a heart rate of 60-94 bpm 24 h after randomisation than in the control group (55% [41 of 75] vs 33% [25 of 75]), with a between-group difference of 23·1% (95% CI 7·1-37·5; p=0·0031). Adverse events were observed in 49 (64%) of 77 patients in the landiolol group and in 44 (59%) of 74 in the control group, with serious adverse events (including adverse events leading to death) in nine (12%) of 77 and eight (11%) of 74 patients. Serious adverse events related to landiolol occurred in five (6%) of 77 patients, including blood pressure decreases in three patients (4%) and cardiac arrest, heart rate decrease, and ejection fraction decrease occurred in one patient each (1%).
INTERPRETATION: Landiolol resulted in significantly more patients with sepsis-related tachyarrhythmia achieving a heart rate of 60-94 bpm at 24 h and significantly reduced the incidence of new-onset arrhythmia. Landiolol was also well tolerated, but it should be used under appropriate monitoring of blood pressure and heart rate owing to the risk of hypotension in patients with sepsis and septic shock.
FUNDING: Ono Pharmaceutical Co.
参考来源
- Kakihana Y, Nishida O, Taniguchi T, et al. Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2020. PMID: 32243865. doi:10.1016/S2213-2600(20)30037-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。